The One-Two Punch of Modified Citrus Pectin
It may be hard to believe but the pith of an orange peel provides impressive support to the immune system while equally supporting a healthy inflammatory response. That pale, spongy layer on citrus fruits is the starting material for modified citrus pectin (MCP). Once the starting material is collected, there is a complex, proprietary process to modify it into the form of a dietary supplement. The modification process creates a small molecule that can be more easily absorbed by the body. The MCP can then enter the bloodstream where it can support health on the cellular level.
A key mechanism of action with MCP is its ability to bind to galectin-3. By reducing the build-up of excess galectin-3, MCP supports health on many levels. MCP also has antioxidant activity and can help support healthy fibrosis production.
Because not all MCP products are equal, practitioners are encouraged to look for these key characteristics:
- Low lead, “clean” starting material because pith can be a chelator of lead
- Low molecular weight for optimal enhanced absorption
- Manufactured by a company adhering to GMP high-quality standards
- Confirmation that the product has been used in clinical studies to avoid the “borrowed science” effect
Research shows that MCP has no toxicity and is considered safe for both short-term and long-term use. In fact, the FDA has given MCP GRAS status, which means it is “generally recognized as safe.” This status is awarded when there is consensus by experts that the substance is safe for human consumption. Since MCP is a dietary fiber, some people may experience loose stools when the supplement is first taken. In general, it’s best to take MCP on an empty stomach at least 30 minutes before or after eating or taking other supplements or medications.
So if you’re looking for that potent one-two punch for your patients, consider adding MCP to their protocol.
Abu-Elsaad NM, Elkashef WF. Canadian Journal of Physiology and Pharmacology. 2016;94(5):554-562.
Keizman D, Frenkel MA, Edwards TM, et al. Journal of Clinical Oncology. 2017(35)15.